Continued Strategic Progress in Challenging Markets Webcast Available at 7:01AM BST, 2.01 EDT LONDON–(BUSINESS WIRE)–Genus (LSE:GNS), a leading global animal genetics company, today announces its preliminary results for the year ended 30 June 2022. The full report has been made available on the investors section of the Genus plc website. The Company will discuss its … [Read more…]
Two separate analyses1,2 presented at the Migraine Trust International Symposium (MTIS) demonstrate the effectiveness of AJOVY▼(fremanezumab) for the treatment of migraine in patients with migraine and co-morbid depression Depression and anxiety are common co-morbidities experienced by around half of all patients with migraine3,4 and are associated with more pain, disability and a reduced quality of … [Read more…]
MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce Sensorion’s participation, in-person, in the Inner Ear Biology Workshop, taking place on September 10-13, 2022, in Trieste, … [Read more…]
SAINT-HERBLAIN, France & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe. Under the terms of the agreement, … [Read more…]
MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 15, 2022, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first half of 2022. Speakers during the … [Read more…]
– FDA Advisory Committee voted 7:2 that the available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS – If approved, AMX0035 will be the first treatment in ALS that has demonstrated a significant slowing of disease progression and functional decline, as well as extended survival, in a randomized, … [Read more…]
Late-Breaking presentation of phase 2 results from a clinical trial of GX-188E in combination with KEYTRUDA® (pembrolizumab) demonstrates anti-tumor benefit in heavily pre-treated, recurrent and advanced cervical cancer SEOUL, South Korea–(BUSINESS WIRE)–Genexine (KOSDAQ: 095700), a publicly traded, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet … [Read more…]
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$bgne #beigene—BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Company will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on … [Read more…]
NASHVILLE, Tenn.–(BUSINESS WIRE)–HCA Healthcare, Inc. (NYSE: HCA) is scheduled to present at the following healthcare conference: September 8, 2022 at 10:00 am CDT at the 2022 Wells Fargo Leveraged Finance Conference at the Gaylord Opryland Resort Hotel in Nashville, TN. A link to the live audio webcast, where applicable, and copies of any related presentation … [Read more…]
– Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab – – Median progression-free survival was not yet reached with the combination of cabozantinib, nivolumab and ipilimumab versus 11.3 months with nivolumab combined with ipilimumab – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. … [Read more…]
